SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Hematology Consultation — Marie Curie
| Patient | Marie Curie |
|---|
| Date of birth | 1959-11-07 |
|---|
| Identifiers | MRN HR-ET013-SYN; SSN (made up) 000-13-2758 |
|---|
| Document date | 2026-05-18 |
|---|
| Author | Lukas Brenner, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Pancytopenia with a low reticulocyte count in a 66-year-old physicist with decades of occupational radiation exposure, suspicious for marrow failure. Please assess urgently, with bone marrow aspirate and biopsy, cytogenetics, and PNH testing, and advise on treatment. [S]
Urgency: Urgent, within one week. [S]
Questions for the consultant:
- Is this aplastic anemia, and does the marrow exclude hypoplastic myelodysplasia, a PNH clone, or another cause?
- How severe is it, and what treatment do you recommend?
- What transfusion, bleeding, and infection precautions should apply while her counts are this low?
- Could her decades of radiation work have caused this, and what should change in her laboratory?
- What monitoring should primary care share during treatment?
History of Present Illness
Madame Curie is seen at the request of Dr. Nwosu one week after a blood count showed pancytopenia with a low reticulocyte count. She is less breathless since the transfusion but still tires by midafternoon. New bruises appear on her arms and shins without injury; she has had no nosebleeds, gum bleeding, blood in the urine or stool, or further fever. Glare in the right eye is slowing her reading. She has worked for decades with radium sources and X-ray equipment and has stopped laboratory work since the last visit. She takes no medicines and wants the full data and plan. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Marie Curie, born Maria Sklodowska, was born in Warsaw on November 7, 1867, the daughter of a secondary-school teacher. [D]
- In 1920 Curie learned that she had a double cataract; her vision became so impaired that she wrote lecture notes in huge letters, and only after four operations, between 1923 and 1930, could she again do exacting laboratory work and drive a car. [D]
- In a November 1920 letter to her sister Bronya, Curie wrote that radium perhaps had something to do with her troubles, but that this could not be affirmed with certainty. [D]
- Her cataracts are regarded as an early documented example of radiation cataract. [R]
- Curie's fingers were severely burned from handling radioactive materials with her bare hands while preparing radium standards. [D]
- During the First World War Curie directed the Red Cross Radiology Service, set up France's first military radiology centers, and equipped 20 mobile X-ray vehicles, the first ready by late October 1914. [D]
- In 1925 Curie took part in a French Academy of Medicine commission that recommended lead screens and periodic blood tests for workers handling radioactive materials, and she required Radium Institute staff to have regular blood counts. [D]
- In May 1934 Curie went home sick from her laboratory and never returned; specialists who suspected tuberculosis advised a sanatorium stay, and a medical expert from Geneva diagnosed an incurable blood disorder. [D]
- Curie's mother, Bronislawa Sklodowska, died in May 1878 of tuberculosis at age 42, after a five-year illness, when Marie was ten; her eldest sister, Zosia, died of typhus caught from a boarder when Marie was eight. [D]
- With Pierre Curie, whom she married in 1895, she discovered polonium and radium; she shared the 1903 Nobel Prize in Physics, received the 1911 Nobel Prize in Chemistry, and directed the Curie Laboratory of the Radium Institute. Pierre Curie died in 1906. [D]
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Cyclosporine (modified) 100 mg oral capsule, one capsule twice daily, dose adjusted to trough levels by hematology | One capsule by mouth twice daily; hematology adjusts the dose to trough levels | Oral route | 2026-05-18 | active | S |
| Eltrombopag 75 mg oral tablet, two tablets (150 mg) once daily on an empty stomach | Two tablets by mouth once daily, two hours before or four hours after food, dairy, or antacids | Oral route | 2026-05-18 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily during immunosuppression | One tablet by mouth twice daily | Oral route | 2026-05-18 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Severe aplastic anemia: pancytopenia with a low reticulocyte count, confirmed by a hypocellular bone marrow; attributed to cumulative occupational ionizing radiation; linked to the documented 1934 diagnosis | active | confirmed |
D61.2 | S — Synthetic modern diagnosis; the 1934 report remains D and the radiation cause is R. |
| Occupational exposure to ionizing radiation over decades of radium research and X-ray work | active | confirmed |
Z57.1 | S — Synthetic modern coding of the documented exposure history. |
| Chronic radiodermatitis of the fingertips, with thin, scarred skin | active | confirmed |
L58.1 | S — Synthetic skin finding linked to the documented finger burns. |
Physical Exam
Vital signs recorded on 2026-05-18; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Pale, alert, precise, and composed |
| Skin | Scattered bruises on the forearms and shins; a few petechiae on the lower legs; thin, scarred fingertip skin |
| Mouth | No gum bleeding or blood blisters; no ulcers |
| Lymph nodes | No lymphadenopathy |
| Abdomen | No hepatomegaly or splenomegaly |
| Heart | Regular rhythm, pulse 92; soft flow murmur |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-05-18 | Hemoglobin [Mass/volume] in Blood | 8.9 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-05-18 | Leukocytes [#/volume] in Blood by Automated count | 1.8 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 2026-05-18 | Neutrophils [#/volume] in Blood by Automated count | 0.4 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 2026-05-18 | Platelets [#/volume] in Blood by Automated count | 15 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 2026-05-18 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 | fL | 80-100 fL | High | S |
| 2026-05-18 | Reticulocytes [#/volume] in Blood by Automated count | 12 | 10*3/uL | 25-100 10*3/uL | Low | S |
Assessment
- Severe aplastic anemia, newly confirmed (D61.2). Marrow cellularity about 10 percent with no dysplasia, fibrosis, or malignant cells; normal cytogenetics exclude hypoplastic myelodysplasia, and there is no PNH clone. Normal B12, folate, LDH, and bilirubin and no organomegaly or lymphadenopathy point away from other causes. Neutrophils 0.4, platelets 15, and reticulocytes 12 thousand per microliter meet the criteria for severe, not very severe, aplastic anemia; hemoglobin is 8.9 g/dL after the transfusion. An immune mechanism cannot be excluded, so standard immunosuppression is chosen; transplant is not chosen at 66. [S]
- Checks before immunosuppression. Creatinine 0.78 mg/dL and potassium 4.1 from one week ago allow cyclosporine. No ALT and no hepatitis B, hepatitis C, HIV, CMV, or EBV serology are on record before treatment; bilirubin was 0.6 mg/dL a week ago. With neutrophils 0.4 and platelets 15, treatment starts today and these tests are to follow with the next blood draw. [S]
- Occupational exposure to ionizing radiation (Z57.1). Decades of exposure, recorded in her history. The link to her marrow failure is probable but not proven, so immunosuppression is still offered in case an immune mechanism contributes. [S]
- Chronic radiodermatitis of the fingertips (L58.1). Stable thin, scarred skin without ulceration; vulnerable to injury while platelets are low. [S]
Data reviewed: The blood count, reticulocyte count, and nutritional, hemolysis, and kidney studies from one week ago; today's blood count and reticulocyte count; and today's bone marrow aspirate and trephine biopsy with cytogenetics and PNH flow cytometry. No liver enzymes or viral serology are on record. [S]
Plan of Treatment
- Horse antithymocyte globulin as a four-day infusion course in the hematology unit, starting today. [S]
- Cyclosporine (modified) 100 mg twice daily from today, with the dose adjusted by hematology to trough levels; first trough within the first weeks. [S]
- Eltrombopag 150 mg once daily from today, on an empty stomach two hours before or four hours after food, dairy, or antacids. [S]
- Acyclovir 400 mg twice daily as antiviral prophylaxis throughout immunosuppression; Pneumocystis prophylaxis is not needed with this regimen. [S]
- Send ALT and hepatitis B, hepatitis C, HIV, CMV, and EBV serology with the next blood draw. [S]
- Weekly blood count with differential and reticulocytes through the hematology day unit for the first months; creatinine, potassium, and ALT every two weeks; blood pressure and weight at every visit. [S]
- Irradiated, leukocyte-depleted blood products from now on (blood bank flag placed). Red cells for symptoms or hemoglobin below 7 to 8 g/dL; platelet support per the hematology unit protocol during the antithymocyte globulin course, and for bleeding afterward. [S]
- No antibacterial or antifungal prophylaxis for now; review under local policy if neutrophils stay at or below 0.5. Same-day assessment for a temperature of 38 °C or higher, bleeding precautions, and no aspirin or NSAIDs; written plan given. [S]
- Inactivated vaccines only; no live vaccines. [S]
- No further occupational radiation exposure while counts recover, and an occupational health review of shielding and dosimetry for her laboratory staff. [S]
- Emollient and protection from injury for the fingertips while platelets are low. [S]
- Formal response assessment at three and six months; counts are not expected to rise in the first weeks. [S]
- Discussed with Dr. Nwosu by telephone today. The marrow results, the severity criteria, and the treatment plan were reviewed in detail with the patient, who agreed to start treatment today. [S]
- Follow-up: Hematology unit this week for the antithymocyte globulin course, then weekly blood counts through the hematology day unit, with hematology managing the cyclosporine dose. Primary care review in three weeks with blood counts, kidney function, potassium, and ALT, and a review of the right-eye glare. [S]